Merck KGaA (MRK) Panoramica del titolo
Merck KGaA opera come azienda scientifica e tecnologica in Germania. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 5/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per MRK dai nostri controlli di rischio.
MRK Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Merck KGaA
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €128.20 |
| Massimo di 52 settimane | €131.65 |
| Minimo di 52 settimane | €100.70 |
| Beta | 0.78 |
| Variazione di 1 mese | 14.57% |
| Variazione a 3 mesi | 1.91% |
| Variazione di 1 anno | 9.57% |
| Variazione a 3 anni | -21.85% |
| Variazione a 5 anni | -12.64% |
| Variazione dall'IPO | 726.61% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento della narrazione • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.Aggiornamento della narrazione • Apr 30
MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside
The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Aggiornamento della narrazione • Apr 15
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
Aggiornamento della narrazione • Apr 01
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.Aggiornamento della narrazione • Mar 18
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.Aggiornamento della narrazione • Mar 04
MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.Aggiornamento della narrazione • Feb 18
MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.Aggiornamento della narrazione • Feb 03
MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.Aggiornamento della narrazione • Jan 20
MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.Aggiornamento della narrazione • Jan 06
MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.Aggiornamento della narrazione • Dec 21
MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.Aggiornamento della narrazione • Dec 07
MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.Aggiornamento della narrazione • Nov 23
MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.Aggiornamento della narrazione • Nov 03
MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.Aggiornamento della narrazione • Oct 20
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.Aggiornamento della narrazione • Sep 04
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.Articolo di analisi • Jul 24
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Jul 03
Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 19x in Germany, you could be forgiven for feeling...
Nuova narrazione • Nov 24
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.Rendimenti per gli azionisti
| MRK | DE Pharmaceuticals | DE Mercato | |
|---|---|---|---|
| 7D | 6.5% | 6.4% | 3.9% |
| 1Y | 9.6% | 26.5% | 2.6% |
Ritorno vs Industria: MRK ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento 26.5 % nell'ultimo anno.
Rendimento vs Mercato: MRK ha superato il mercato German che ha restituito 2.6 % nell'ultimo anno.
Volatilità dei prezzi
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Prezzo delle azioni stabile: MRK non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di MRK è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1668 | 59,077 | Kai Beckmann | www.emdgroup.com |
Merck KGaA opera come società scientifica e tecnologica in Germania. Opera attraverso i segmenti Life Science, Healthcare ed Electronics. Il segmento Life Science dell'azienda offre strumenti, prodotti chimici e attrezzature per laboratori accademici, produttori biotecnologici e farmaceutici, nonché per il settore industriale.
Merck KGaA Riepilogo dei fondamenti
| MRK statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €56.52b |
| Utili (TTM) | €2.53b |
| Ricavi(TTM) | €20.96b |
22.0x
Rapporto P/E2.7x
Rapporto P/SMRK è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MRK Conto economico (TTM) | |
|---|---|
| Ricavi | €20.96b |
| Costo del fatturato | €8.61b |
| Profitto lordo | €12.35b |
| Altre spese | €9.82b |
| Utili | €2.53b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 06, 2026
| Utile per azione (EPS) | 5.82 |
| Margine lordo | 58.93% |
| Margine di profitto netto | 12.08% |
| Rapporto debito/patrimonio netto | 40.4% |
Come si è comportato MRK nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.7%
Rendimento attuale del dividendo38%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 21:02 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Merck KGaA è coperta da 43 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |